(ben-da-muss-teen) ,


(trade name)


Therapeutic: antineoplastics
Pharmacologic: benzimidazoles
Pregnancy Category: D


Chronic lymphocytic leukemia.Indolent B-cell non-Hodgkin's lymphoma that has progressed during or within 6 mo of receiving rituximab or a rituximab-containing regimen.


Damages DNA resulting in death of rapidly replicating cells.

Therapeutic effects

Decreased proliferation of leukemic cells.
Death of lymphoma cells.


Absorption: IV administration results in complete bioavailability.
Distribution: Distributes freely into red blood cells.
Protein Binding: 94–96%.
Metabolism and Excretion: Mostly metabolized (partially by the CYP1A2 enzyme system); 90% excreted in feces; some renal elimination. Although metabolites have antineoplastic activity, levels are extremely low.
Half-life: 40 min.

Time/action profile (blood levels)

IVrapidend of infusionunknown


Contraindicated in: Hypersensitivity to bendamustine or mannitol;Moderate-to-severe renal impairment (CCr <40 mL/min;Moderate or severe hepatic impairment; Obstetric / Lactation: Pregnancy or lactation.
Use Cautiously in: Patients at risk for tumor lysis syndrome (concurrent allopurinol recommended);Mild hepatic impairment;Mild to moderate renal impairment;Patients with child-bearing potential; Geriatric: May be more susceptible to adverse reactions; Pediatric: Effectiveness not established.

Adverse Reactions/Side Effects

Central nervous system

  • fatigue
  • weakness


  • cough


  • nausea (most frequent)
  • vomiting (most frequent)
  • diarrhea


  • toxic epidermal necrolysis
  • stevens-johnson syndrome
  • skin reactions


  • anemia (most frequent)
  • leukopenia
  • neutropenia
  • thrombocytopenia


  • hyperuricemia


  • malignancy (life-threatening)
  • tumor lysis syndrome (life-threatening)
  • allergic reactions including anaphylaxis
  • fever (most frequent)
  • infusion reactions


Drug-Drug interaction

CYP1A2 inhibitors, including fluvoxamine and ciprofloxacin may ↑ levels of bendamustine and ↓ levels of active metabolites; consider alternative treatments.CYP1A2 inducers, including omeprazole and smoking may ↓ levels of bendamustine and ↑ levels of its active metabolites; consider alternative treatments.


Chronic Lymphocytic Leukemia
Intravenous (Adults) 100 mg/m2 on days 1 and 2 of a 28-day cycle, up to 6 cycles; dose modification required for toxicity.
Non-Hodgkin's Lymphoma
Intravenous (Adults) 120 mg/m2 on days 1 and 2 of a 21-day cycle, up to 8 cycles; dose modification required for toxicity.


Solution for injection: 45 mg/0.5 mL, 180 mg/2 mL

Nursing implications

Nursing assessment

  • Monitor for bone marrow depression. Assess for bleeding (bleeding gums, bruising, petechiae, guaiac stools, urine, and emesis) and avoid IM injections and taking rectal temperatures if platelet count is low. Apply pressure to venipuncture sites for 10 min. Assess for signs of infection during neutropenia; anemia may occur; monitor for increased fatigue, dyspnea, and orthostatic hypotension.
  • Monitor for symptoms of infusion reactions (fever, chills, pruritus, rash). May rarely cause severe allergic and anaphylactic reactions, especially in second and subsequent cycles. Discontinue therapy if severe reactions occur. Ask patient about symptoms suggestive of infusion reactions after first cycle of therapy. Consider using antihistamines, antipyretics, and corticosteroids in patients who previously experienced Grade 1 or 2 reactions. Consider discontinuation of therapy in patients with Grade 3 or 4 reactions.
  • Assess for tumor lysis syndrome. Usually occurs during first cycle of bendamustine. May lead to acute renal failure and death. Maintain adequate volume status, close monitoring of blood chemistry, especially potassium and uric acid levels, and use allopurinol during first 1–2 wk of therapy in high risk patients.
  • Assess for skin reactions (rash, toxic skin reactions, bullous exanthema). Withhold or discontinue therapy if reactions are progressive or severe. If non-hematologic toxicity is ≥ Grade 3, reduce dose to 50 mg/m2 on Days 1 and 2 of each cycle.
  • Monitor intake and output, appetite, and nutritional intake. Assess for nausea and vomiting. Administration of an antiemetic before and during therapy and adjusting diet as tolerated may help maintain fluid and electrolyte balance and nutritional status.
  • Monitor IV site for redness, swelling, pain, infection, and necrosis frequently during an after infusion. Extravasation may cause erythema, marked swelling, and pain.
  • Lab Test Considerations: Monitor CBC with differential and platelet count before and during therapy. The hematologic nadirs occur wk 3. Recovery usually occurs in 28 days. Withhold dose and notify physician if ANC is ≥1 × 109/L and platelet count is ≥75,000 × 109/L.For patients treated for chronic lymphocytic leukemia: If hemotologic toxicity ≥Grade 3, reduce dose to 50 mg/m2 on Days 1 and 2. If Grade 3 or greater toxicity recurs, reduce dose to 25 mg/m2 on Days 1 and 2. For patients treated for non-Hodgkin's lymphoma: If hematologic toxicity ≥Grade 4, reduce dose to 90 mg/m2 on Days 1 and 2. If Grade 4 or greater toxicity recurs, reduce dose to 60 mg/m2 on Days 1 and 2.
    • Monitor blood chemistry, especially serum potassium and uric acid before and periodically during therapy. Allopurinol may be used during first wk of therapy to prevent tumor lysis syndrome.

Potential Nursing Diagnoses

Risk for infection (Side Effects)


  • high alert: Fatalities have occurred with chemotherapeutic agents. Before administering, clarify all ambiguous orders; double check single, daily, and course-of-therapy dose limits; have second practitioner independently double-check original order, calculations, and infusion pump settings.
  • Intravenous Administration
  • pH: 2.5–3.5.
  • Prepare solution in a biologic cabinet. Wear gloves and safety glasses while handling medication. Discard equipment in designated containers.
  • Intermittent Infusion: Diluent: Withdraw volume needed and transfer to 500 mL of 0.9% NaCl or 2.5% dextrose/0.45% NaCl. Mix thoroughly. Solution should be clear, colorless to pale yellow. Do not administer solutions that are discolored or contain a precipitate. Concentration: 0.2–0.7 mg/mL.
    • Diluted solution is stable for 24 hr when refrigerated or 2 hr at room temperature; administration must be completed within this period. Solution contains no preservatives; discard unused solution.
  • Rate: Chronic Lymphocytic Leukemia—Administer 100 mg/m2 over 30 min. Non-Hodgkin's lymphoma—Administer 120 mg/m2 over 60 min.
  • Additive Incompatibility: Do not admix or dilute with other solutions or medication.

Patient/Family Teaching

  • Instruct patient to notify health care professional if fever; chills; sore throat; signs of infection; lower back or side pain; difficult or painful urination; shortness of breath; fatigue; bleeding gums; bruising; petechiae; or blood in urine, stool, or emesis occurs. Caution patient to avoid crowds and persons with known infections. Instruct patient to use soft toothbrush and electric razor. Caution patients to avoid alcoholic beverages and products containing aspirin or NSAIDs; may precipitate gastric bleeding.
  • Instruct patient to notify health care professional immediately if symptoms of allergic reactions (rash, facial swelling, or difficulty breathing) or nausea, vomiting or diarrhea occur.
  • May cause tiredness. Caution patient to avoid driving and other activities requiring alertness until response to medication is known.
  • Instruct patient not to receive any vaccinations without advice of health care professional.
  • Advise patient this medication may have teratogenic effects. Contraception should be used by both men and women during and for at least 3 mo following completion of therapy. Advise women not to breast feed during therapy.
  • Emphasize need for periodic lab tests to monitor for side effects.

Evaluation/Desired Outcomes

  • Improvement in hematologic parameters.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
Patients in the second arm received physician's choice of either rituximab in combination with idelalisib or rituximab in combination with bendamustine.3,4
ENPNewswire-August 7, 2019--MorphoSys Discloses Biomarker to Stratify Patient Population in B-MIND Study of Tafasitamab plus Bendamustine in r/r DLBCL
The number of prior treatment regimens including anti-CD20 antibody, bendamustine and anthracyclines ranged from one to nine, with a median of three.
The ASCEND trial compared Calquence with the investigator's choice of rituximab combined with idelalisib or bendamustine in patients with relapsed or refractory CLL.
Reportedly, the ASCEND trial compared Calquence with the physician's choice of rituximab combined with idelalisib (IdR) or bendamustine (BR) in patients with relapsed or refractory CLL.
It was approved in combination with bendamustine plus Rituxan[R] (rituximab) (BR) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least two prior therapies.
The approval is for the use of Polivy in combination with another Roche drug, Rituxan, as well as chemotherapy drug bendamustine. It is used with patients with relapsed or refractory large B-cell lymphoma who have received at least two prior therapies.
The treatment of choice in patients who are not eligible for high-dose chemo with ASCT (60%) [5] is GemOx (gemcitabine-oxaliplatin), bendamustine, gemcitabine, dexamethasone, and cisplatin (GDP), lenalidomide (activated B-cell - non--germinal center B-cell (GCB) and ibrutinib (non-GCB) [8-12].
Biotechnology company Genmab A/S (CPH:GEN) reported on Thursday that topline results from the phase III study of Arzerra (ofatumumab) plus bendamustine did not meet the primary endpoint of improved progression-free survival (PFS) in patients with indolent B-cell non-Hodgkin's lymphoma (iNHL) who were unresponsive to rituximab or a rituximab-containing regimen, as compared to those given bendamustine alone.
A 61-year-old man with past medical history of sarcoidosis, deep vein thrombosis on rivaroxaban, and CLL treated with bendamustine and rituximab complicated by neutropenia presented to the outpatient office with (four) days of fevers and scant hemoptysis.
has received final approval of its Abbreviated New Drug Application (ANDA) for bendamustine hydrochloride powder for infusion, 25 mg/vial and 100 mg/vial.